Compass pathways stock forecast.

Fresh off IPO, Compass sees mushrooming opportunity in psilocybin....CMPS Psychedelic company Compass Pathways PLC (CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K....It's a gradual path, however, and the stock hasn't moved much overall since the company last provided a financial update on Aug. 11. But in the month of September, Compass shares slid 11.9% ...I last covered the company for Seeking Alpha back in September 2021 when Compass' share price traded at $32.6 and its market cap was ~$1.4bn, and despite arguably making some significant progress ...TipRanksDespite having an IPO just three months ago, Compass Pathways (NASDAQ: CMPS) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ...

Compass Pathways Plc ADR (CMPS) shares have gone down -22.59% during the last six months, with a year-to-date growth rate less than the industry average at -3.70% against 5.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 64.40% this quarter and then jump 7.00% in the …WebIn the same quarter last year, COMPASS Pathways's earnings per share (EPS) was -$0.44. COMPASS Pathways is expected to release next earnings on 02/26/2024, with ...

Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ...

A. While ratings are subjective and will change, the latest Compass Pathways ( CMPS) rating was a reiterated with a price target of $0.00 to $21.00. The current price Compass Pathways ( CMPS) is ...Dec 26, 2020 · Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ... Oct 22, 2021 · And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ... About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

In the same quarter last year, COMPASS Pathways's earnings per share (EPS) was -$0.44. COMPASS Pathways is expected to release next earnings on 02/26/2024, with ...

Overall, the consensus among analysts is that Compass Pathways has a promising future ahead. CMPS Stock Analysis: Fluctuating Prices and Negative Earnings Growth, but Positive Forecast for the Future. On May 11, 2023, CMPS stock opened at the same price as the previous close, which was 8.59. Throughout the day, the stock’s price fluctuated ...

Find the latest Alpha Lithium Corporation (APHLF) stock quote, history, news and other vital information to help you with your stock trading and investing.Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebHow to buy COMPASS Pathways PLC stock on Stash. 1. Enter the amount you'd like to invest in COMPASS Pathways PLC stock, then proceed to checkout. Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.WebDec 1, 2023 · COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83

And the biotechnology industry's average price-to-sales multiple is 4.7. Thus, if Compass manages to capture a mere 10% of that per year, it could be bringing in $139 million in revenue. Assuming ...Oct 26, 2023 · Compass Pathways Plc stock forecasts for 2023-2027. Date: Open Price: Close Price: Change: Compass Pathways Plc Stock Forecast for 2023: January 2023: 2.04: 1.02-50% ... Dec 1, 2023 · COMPASS Pathways (CMPS) Stock Forecast & Price Target $6.05 +0.22 (+3.77%) (As of 11/22/2023 ET) Compare Today's Range $5.80 $6.07 50-Day Range $5.27 $9.92 52-Week Range $5.01 $11.48 Volume 169,831 shs Average Volume 347,447 shs Market Capitalization $374.50 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Compass Pathways Stock Performance Analysis: August 4, 2023 On August 4, 2023, the stock performance of Compass Pathways (CMPS) was closely watched by investors and analysts. As per the data sourced from CNN Money, let’s delve into the key figures and analyze the implications for the company.

View Our Latest Research Report on COMPASS Pathways. COMPASS Pathways Price Performance. COMPASS Pathways stock opened at $6.01 on Friday. The firm has a market cap of $372.02 million, a P/E ratio of -2.32 and a beta of 2.56. The stock’s 50 day moving average is $6.75 and its 200 day moving average is $7.90.LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...Compass Pathways has also returned positive data from a Phase 2 trial of its psilocybin formulation, using a similar "monitored sessions" approach, even providing music, soft furnishings and a ...COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting? This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a …Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target....CMPS Compass Pathways (CMPS) has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target....Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... However, the expert forecasts the stock moving up to $25, implying 252% upside potential. If so, FAT would easily be one of the sin stocks to buy. Compass Pathways (CMPS)CMPS : Long term COMPASS Pathways plc stock forecast for 2022, 2023 (1 year) - 2025 - 2027 (5 year) - 2030, and 2032 (10 year). Forecast for 2024 Jan. is $6.19 ...LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ...

COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ...

Based on short-term price targets offered by six analysts, the average price target for COMPASS Pathways PLC Sponsored ADR comes to $48.67. The forecasts range from a low of $19.00 to a high...We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases. SEC filings & annual reports. Our annual review. Stock information. Stock quote & chart. Historical price lookup. Corporate governance.WebDescription. Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways …COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...Price vs Fair Value View History CMPS is trading at a 62% discount. Price $5.94 Nov 17, 2023 Fair Value $72.99 Nov 17, 2023 Uncertainty Extreme 1-Star Price $86.85COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ...Get a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...WebLONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.Instagram:https://instagram. private health insurance companies georgiais jepi a safe investmentwaka waka easewer line insurance colorado Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...WebAccording to COMPASS Pathways's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.54468. At the end of 2022 ... is tesla a good stocksell xbox 360 Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The average price target for CMPS is …Web how to use ameritrade Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...COMPASS Pathways PLC Sponsored ADR (CMPS) Just Flashed Golden Cross Signal: Do You Buy? 09/08/23-8:55AM EST Zacks Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat 05/05/23-11:16AM EST Zacks